GLP-1 obesity care in 2026: WHO's first guideline and ADA Standards update
Industry Buzz
This move aims to bridge the longstanding treatment gap in low- and middle-income countries … where high drug costs have limited access to such therapies.
—Kanimozhi Mani
When it comes to GLP-1s, the question has moved from “Should we prescribe them?” to “How do we prescribe them responsibly, selectively, and for the long haul?” That shift happened because the policy, guidelines, and dosing environment changed almost at once.
In December 2025, the World Health Organization (WHO) issued its first global guideline on GLP-1 therapies for adults with obesity, framing obesity as a chronic, relapsing disease, and making conditional recommendations for long-term use of liraglutide, semaglutide, and tirzepatide in adults with obesity.[]
The WHO also placed GLP-1 receptor agonists on the Model List of Essential Medicines for high-risk diabetes care, signaling that these drugs are no longer being treated as boutique metabolic products but as medicines with global health-system implications.[]
“This move aims to bridge the longstanding treatment gap in low- and middle-income countries … where high drug costs have limited access to such therapies. Their recognition as essential medicines enables [prioritization] of limited resources, facilitates equitable pricing, and supports the development of generics and biosimilars post-patent expiry,” wrote Kanimozhi Mani in the Journal of Diabetes & Metabolic Disorders.[]
Additionally, the American Diabetes Association (ADA) 2026 Standards of Care recommend that in adults with type 2 diabetes and biopsy-proven MASH or high fibrosis risk, GLP-1 receptor agonist therapy—often in combination with pioglitazone—can be considered due to potential MASH benefit.[]
The ADA also expanded the obesity-management conversation in type 1 diabetes, naming GLP-1 receptor agonists and metabolic surgery as options in selected patients with obesity.[]
And in March 2026, the US Food and Drug Administration (FDA) approved Wegovy HD, a 7.2 mg once-weekly semaglutide injection, for chronic weight management in certain adults.[]
Novo Nordisk announced nationwide US availability in April, citing data showing average weight loss of roughly 21% at 72 weeks in adults with obesity if all patients stayed on therapy, and roughly 19% regardless of whether patients stayed on therapy.[]
For primary care prescribers, this is a different clinical landscape. The modern GLP-1 visit is less about defending anti-obesity medication and more about triage.
Who has the most compelling indication? Which option makes the most sense? How long should treatment continue? And what is the plan when insurance, adverse effects, pregnancy planning, patient preference, or weight plateau forces a stop?
Obesity care is becoming risk-stratified
The most important practical point in the WHO guideline is that obesity treatment is being organized around chronic-disease management, not episodic weight loss. Primary care providers cannot prescribe these medications to everyone who meets a BMI threshold. Supply, coverage, cost, tolerability, competing comorbidities, and follow-up capacity all force prioritization.
In practice, the strongest candidates currently are likely to be patients whose obesity is already expressing itself metabolically or mechanically: type 2 diabetes, established cardiovascular disease, obstructive sleep apnea, MASH or elevated fibrosis risk, hypertension, dyslipidemia, CKD risk, severe obesity, or failed prior intensive lifestyle and pharmacologic attempts.
The ADA liver update is especially relevant. For years, MASH lived in a frustrating gap between abnormal ALT, ultrasound steatosis, and “please lose weight.” Now, a patient with type 2 diabetes, obesity, and high fibrosis risk is no longer just a glycemic-management patient. They are a liver-risk patient, a cardiometabolic-risk patient, and often a weight-management patient at the same time.
That doesn’t mean every patient with fatty liver gets a GLP-1 prescription. It does mean PCPs should get more comfortable with fibrosis triage: FIB-4, platelet count, AST/ALT trends, transient elastography when available, and referral pathways for indeterminate or high-risk results.
The agent choice is no longer cosmetic
For years, GLP-1 selection in obesity care was often dictated by coverage. That is still true. But clinically, the choice is becoming more nuanced.
Semaglutide has the broadest public familiarity and now has multiple obesity formulations, including higher-dose injectable semaglutide at 7.2 mg. Tirzepatide offers dual GIP/GLP-1 activity and has produced large weight-loss effects in obesity trials.[]
Liraglutide remains part of the WHO guideline but is administered daily, generally less potent for weight loss, and often less attractive when weekly options are accessible.[]
The arrival of Wegovy HD adds a new question: What do we do with the patient who tolerates semaglutide at 2.4 mg but plateaus above a clinically meaningful target?
The answer should not be automatic escalation. A plateau visit should still ask whether the patient has had a clinically meaningful response, whether cardiometabolic markers improved, whether adverse effects are manageable, whether lean-mass preservation is being addressed, and whether the next dose meaningfully changes the benefit-risk equation.
A higher dose may be reasonable for some patients. But “more semaglutide” is not a substitute for a treatment plan.
Discontinuation is now part of the prescription
Every GLP-1 start should include a stop conversation. That may feel premature during the first visit, but the discontinuation data are too consistent to ignore.
Patients who stopped semaglutide after 68 weeks regained much of the weight they had lost over the following year, with cardiometabolic improvements drifting back toward baseline.[]Tirzepatide withdrawal data tell a similar story: Stopping therapy after substantial initial weight loss led to meaningful regain, while continued treatment maintained or augmented weight reduction.[]
For PCPs, the script should change from “Let’s see how you do on this medication” to “This works best when we treat obesity like hypertension or diabetes: we reassess regularly, but we do not assume short-term therapy will produce permanent disease remission.”
That does not mean every patient needs lifelong full-dose treatment. The field still needs better evidence on tapering, lower-dose maintenance, intermittent treatment, switching strategies, and post-discontinuation support.
Until then, a practical discontinuation plan should include weight and waist monitoring, appetite and satiety review, resistance training, protein adequacy, sleep apnea management, medication review for weight-promoting drugs, and early rescue options if weight regain begins.
The PCP visit needs a new structure
A strong GLP-1 obesity visit in 2026 should feel less like a weight-loss consultation and more like a cardiometabolic risk visit.
Start with asking yourself: Is this uncomplicated obesity, diabetes-associated obesity, MASH-risk obesity, cardiovascular-risk obesity, reproductive-health obesity, sleep-apnea obesity, or severe obesity with mobility limitation?
Then define the primary treatment target. Is the goal 5% to 7% weight loss for glycemic improvement? More than 10% for disease-modifying metabolic benefit? Larger weight loss because of sleep apnea, MASH, mobility, or preoperative goals?
The ADA reminds clinicians that even modest weight loss improves glycemia and cardiovascular risk factors, while sustained loss above 10% may confer broader disease-modifying effects.[]
Next, choose therapy based on indication, contraindications, patient preference, dose burden, history of adverse effects, comorbidities, fertility plans, and coverage. Document why the chosen drug fits the patient’s risk profile.
Finally, schedule maintenance from day one. Follow-up should not stop after the dose escalation period. Monitor response, tolerability, nutrition quality, sarcopenia risk, gallbladder symptoms, pancreatitis red flags, hydration, bowel function, mood, and medication affordability.